Article 06 Jul 2023 CYLTEZO® To Launch On July 1 As The First Interchangeable HUMIRA® Biosimilar United States Healthcare
Article 23 May 2023 Proposed USPTO Fee Changes Could Impact PGR And IPR Filing Strategies Used By Biosimilars United States IP
Article 17 May 2023 Proposed USPTO Fee Changes Will Make It Much More Expensive To Patent And To Challenge Patents On Therapeutics. You Have An Opportunity To Comment... United States IP
Article 22 Mar 2023 Coherus Biosciences Announces Approval Of A Pegfilgrastim Autoinjector United States Healthcare
Article 23 Jan 2023 USPTO Launches The Cancer Moonshot Expedited Examination Pilot Program United States IP
Article 06 Dec 2022 Biocon Biologics Confirms Completion Of Multi-Billion Dollar Acquisition Of Viatris' Global Biosimilars Business United States Healthcare